Q1 2021 Coherus BioSciences Inc Earnings Call Transcript
Welcome to the Q1 2021 Coherus BioSciences, Inc. Earnings Conference Call. My name is Richard, and I'll be your operator for today's call. (Operator Instructions)
I will now turn the call over to McDavid Stilwell, Chief Financial Officer. Mr. Stilwell, you may begin.
Thank you. Good afternoon, everyone, and thank you for joining us. We issued a press release earlier announcing our 2021 first quarter results. This release can be found on the Coherus BioSciences' website.
Today's call includes forward-looking statements regarding Coherus' current expectations. These statements include, but are not limited to, our ability to advance our biosimilar and immuno-oncology product candidates through development and registration, our commercialization of UDENYCA and other potential products in the future, our ability to meet our R&D and SG&A expense guidance for 2021 as well as our uses of capital, all of which involve certain assumptions, risks and uncertainties that are beyond our control and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |